Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153879 | 0.90 | TGFBR1 (0.47) | TGFBR1CYP3A4CYP2C8TGFBR2CCR1 | |
| SCHEMBL4157147 | 0.89 | TGFBR1 (0.50) | TGFBR1CYP3A4CYP2C8TGFBR2CCR1 | |
| SCHEMBL29680885 | 0.83 | CYP2A6 (0.39) | TGFBR1CYP3A4CYP2C8CDK8JAK1 | |
| SCHEMBL24528632 | 0.83 | CYP2A6 (0.39) | TGFBR1CYP3A4CYP2C8CDK8JAK1 | |
| SCHEMBL3796603 | 0.83 | CDK8 (0.49) | TGFBR1CYP3A4CYP2C8TGFBR2CDK8 | |
| SCHEMBL3803436 | 0.80 | TGFBR1 (0.48) | TGFBR1CYP3A4CYP2C8TGFBR2CCR1 | |
| SCHEMBL4168756 | 0.77 | TGFBR1 (0.58) | TGFBR1CYP3A4CYP2C8TGFBR2CCNK | |
| SCHEMBL3794724 | 0.77 | TGFBR1 (0.60) | TGFBR1CYP3A4CYP2C8TGFBR2CCR1 | |
| SCHEMBL3666832 | 0.76 | TGFBR1 (0.44) | TGFBR1CYP3A4CYP2C8TGFBR2CDK8 | |
| SCHEMBL4151363 | 0.75 | TGFBR1 (0.53) | TGFBR1CYP3A4CYP2C8TGFBR2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | TGFBR1 128/4885CYP3A4 111/4885CYP2C8 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.